Composite outcomes in 2.25-mm drug eluting stents

A systematic review

Justin Z. Lee, Nirmal Singh, Gilbert Ortega, See Wei Low, Uday Kanakadandi, F. David Fortuin, Tom Lassar, Kwan S Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Coronary atherosclerosis often involves small-caliber coronaries, yet the safety and efficacy of 2.25-mm DES have been poorly defined, with a general lack of separation of 2.25 with 2.5-mm performance. No randomized head-to-head 2.25. mm DES studies have been reported. There are several single-arm prospective studies, and we aim to systematically review all published specific 2.25-mm data to estimate composite DES-specific performance and highlight current knowledge gaps. Methods: We performed a systematic literature search of PubMed, EMBASE, Web of Science and Cochrane database for clinical trials of 2.25-mm DES. Angiographic and composite clinical outcomes were compared with descriptive statistics. Results: 2.25. mm-Paclitaxel (PES), sirolimus (SES), everolimus (EES) and platinum chromium EES DES-specific outcomes have been reported. Death at 12. months for SES, PES, EES and platinum chromium EES was 1.3%, 3.0%, 1.5%, and 4.4%. Rates of target vessel revascularization at 12. months for SES, PES, EES and platinum chromium EES were 5.7%, 13.3%, 8.8%, and 3.3%. Angiographic outcomes at 9. months to one year were as follows: mean late lumen loss (LLL) for SES, PES, and EES was 0.15. ±. 0.11-mm, 0.28. ±. 0.11-mm, and 0.16. ±. 0.41-mm and mean diameter restenosis for SES, PES, and EES were 29.5. ±. 6.2%, 34.7. ±. 4.2%, and 20.9. ±. 22.5%. Reported stent thrombosis rates for 2.25-mm DES were low ranging from 0% to 2.2% in up to 24-months of follow-up. Conclusions: This systematic review summarizes and tabulates all available specific data on 2.25-mm DES. Based on our descriptive analysis, 2.25-mm DESs have a favorable safety and efficacy profile for the treatment of very small coronary lesions.

Original languageEnglish (US)
Pages (from-to)237-242
Number of pages6
JournalCardiovascular Revascularization Medicine
Volume16
Issue number4
DOIs
StatePublished - Jun 1 2015

Fingerprint

Drug-Eluting Stents
Chromium
Platinum
Safety
Everolimus
Sirolimus
Paclitaxel
PubMed
Stents
Coronary Artery Disease
Thrombosis
Clinical Trials
Databases
Prospective Studies

Keywords

  • 2.25-mm
  • Drug eluting stents
  • Small coronary vessels

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Composite outcomes in 2.25-mm drug eluting stents : A systematic review. / Lee, Justin Z.; Singh, Nirmal; Ortega, Gilbert; Low, See Wei; Kanakadandi, Uday; Fortuin, F. David; Lassar, Tom; Lee, Kwan S.

In: Cardiovascular Revascularization Medicine, Vol. 16, No. 4, 01.06.2015, p. 237-242.

Research output: Contribution to journalArticle

Lee, JZ, Singh, N, Ortega, G, Low, SW, Kanakadandi, U, Fortuin, FD, Lassar, T & Lee, KS 2015, 'Composite outcomes in 2.25-mm drug eluting stents: A systematic review', Cardiovascular Revascularization Medicine, vol. 16, no. 4, pp. 237-242. https://doi.org/10.1016/j.carrev.2015.03.008
Lee, Justin Z. ; Singh, Nirmal ; Ortega, Gilbert ; Low, See Wei ; Kanakadandi, Uday ; Fortuin, F. David ; Lassar, Tom ; Lee, Kwan S. / Composite outcomes in 2.25-mm drug eluting stents : A systematic review. In: Cardiovascular Revascularization Medicine. 2015 ; Vol. 16, No. 4. pp. 237-242.
@article{30f2c5e10ccc43ed8e73dfc05b074d19,
title = "Composite outcomes in 2.25-mm drug eluting stents: A systematic review",
abstract = "Background: Coronary atherosclerosis often involves small-caliber coronaries, yet the safety and efficacy of 2.25-mm DES have been poorly defined, with a general lack of separation of 2.25 with 2.5-mm performance. No randomized head-to-head 2.25. mm DES studies have been reported. There are several single-arm prospective studies, and we aim to systematically review all published specific 2.25-mm data to estimate composite DES-specific performance and highlight current knowledge gaps. Methods: We performed a systematic literature search of PubMed, EMBASE, Web of Science and Cochrane database for clinical trials of 2.25-mm DES. Angiographic and composite clinical outcomes were compared with descriptive statistics. Results: 2.25. mm-Paclitaxel (PES), sirolimus (SES), everolimus (EES) and platinum chromium EES DES-specific outcomes have been reported. Death at 12. months for SES, PES, EES and platinum chromium EES was 1.3{\%}, 3.0{\%}, 1.5{\%}, and 4.4{\%}. Rates of target vessel revascularization at 12. months for SES, PES, EES and platinum chromium EES were 5.7{\%}, 13.3{\%}, 8.8{\%}, and 3.3{\%}. Angiographic outcomes at 9. months to one year were as follows: mean late lumen loss (LLL) for SES, PES, and EES was 0.15. ±. 0.11-mm, 0.28. ±. 0.11-mm, and 0.16. ±. 0.41-mm and mean diameter restenosis for SES, PES, and EES were 29.5. ±. 6.2{\%}, 34.7. ±. 4.2{\%}, and 20.9. ±. 22.5{\%}. Reported stent thrombosis rates for 2.25-mm DES were low ranging from 0{\%} to 2.2{\%} in up to 24-months of follow-up. Conclusions: This systematic review summarizes and tabulates all available specific data on 2.25-mm DES. Based on our descriptive analysis, 2.25-mm DESs have a favorable safety and efficacy profile for the treatment of very small coronary lesions.",
keywords = "2.25-mm, Drug eluting stents, Small coronary vessels",
author = "Lee, {Justin Z.} and Nirmal Singh and Gilbert Ortega and Low, {See Wei} and Uday Kanakadandi and Fortuin, {F. David} and Tom Lassar and Lee, {Kwan S}",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.carrev.2015.03.008",
language = "English (US)",
volume = "16",
pages = "237--242",
journal = "Cardiovascular Revascularization Medicine",
issn = "1553-8389",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Composite outcomes in 2.25-mm drug eluting stents

T2 - A systematic review

AU - Lee, Justin Z.

AU - Singh, Nirmal

AU - Ortega, Gilbert

AU - Low, See Wei

AU - Kanakadandi, Uday

AU - Fortuin, F. David

AU - Lassar, Tom

AU - Lee, Kwan S

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Background: Coronary atherosclerosis often involves small-caliber coronaries, yet the safety and efficacy of 2.25-mm DES have been poorly defined, with a general lack of separation of 2.25 with 2.5-mm performance. No randomized head-to-head 2.25. mm DES studies have been reported. There are several single-arm prospective studies, and we aim to systematically review all published specific 2.25-mm data to estimate composite DES-specific performance and highlight current knowledge gaps. Methods: We performed a systematic literature search of PubMed, EMBASE, Web of Science and Cochrane database for clinical trials of 2.25-mm DES. Angiographic and composite clinical outcomes were compared with descriptive statistics. Results: 2.25. mm-Paclitaxel (PES), sirolimus (SES), everolimus (EES) and platinum chromium EES DES-specific outcomes have been reported. Death at 12. months for SES, PES, EES and platinum chromium EES was 1.3%, 3.0%, 1.5%, and 4.4%. Rates of target vessel revascularization at 12. months for SES, PES, EES and platinum chromium EES were 5.7%, 13.3%, 8.8%, and 3.3%. Angiographic outcomes at 9. months to one year were as follows: mean late lumen loss (LLL) for SES, PES, and EES was 0.15. ±. 0.11-mm, 0.28. ±. 0.11-mm, and 0.16. ±. 0.41-mm and mean diameter restenosis for SES, PES, and EES were 29.5. ±. 6.2%, 34.7. ±. 4.2%, and 20.9. ±. 22.5%. Reported stent thrombosis rates for 2.25-mm DES were low ranging from 0% to 2.2% in up to 24-months of follow-up. Conclusions: This systematic review summarizes and tabulates all available specific data on 2.25-mm DES. Based on our descriptive analysis, 2.25-mm DESs have a favorable safety and efficacy profile for the treatment of very small coronary lesions.

AB - Background: Coronary atherosclerosis often involves small-caliber coronaries, yet the safety and efficacy of 2.25-mm DES have been poorly defined, with a general lack of separation of 2.25 with 2.5-mm performance. No randomized head-to-head 2.25. mm DES studies have been reported. There are several single-arm prospective studies, and we aim to systematically review all published specific 2.25-mm data to estimate composite DES-specific performance and highlight current knowledge gaps. Methods: We performed a systematic literature search of PubMed, EMBASE, Web of Science and Cochrane database for clinical trials of 2.25-mm DES. Angiographic and composite clinical outcomes were compared with descriptive statistics. Results: 2.25. mm-Paclitaxel (PES), sirolimus (SES), everolimus (EES) and platinum chromium EES DES-specific outcomes have been reported. Death at 12. months for SES, PES, EES and platinum chromium EES was 1.3%, 3.0%, 1.5%, and 4.4%. Rates of target vessel revascularization at 12. months for SES, PES, EES and platinum chromium EES were 5.7%, 13.3%, 8.8%, and 3.3%. Angiographic outcomes at 9. months to one year were as follows: mean late lumen loss (LLL) for SES, PES, and EES was 0.15. ±. 0.11-mm, 0.28. ±. 0.11-mm, and 0.16. ±. 0.41-mm and mean diameter restenosis for SES, PES, and EES were 29.5. ±. 6.2%, 34.7. ±. 4.2%, and 20.9. ±. 22.5%. Reported stent thrombosis rates for 2.25-mm DES were low ranging from 0% to 2.2% in up to 24-months of follow-up. Conclusions: This systematic review summarizes and tabulates all available specific data on 2.25-mm DES. Based on our descriptive analysis, 2.25-mm DESs have a favorable safety and efficacy profile for the treatment of very small coronary lesions.

KW - 2.25-mm

KW - Drug eluting stents

KW - Small coronary vessels

UR - http://www.scopus.com/inward/record.url?scp=84930818802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930818802&partnerID=8YFLogxK

U2 - 10.1016/j.carrev.2015.03.008

DO - 10.1016/j.carrev.2015.03.008

M3 - Article

VL - 16

SP - 237

EP - 242

JO - Cardiovascular Revascularization Medicine

JF - Cardiovascular Revascularization Medicine

SN - 1553-8389

IS - 4

ER -